Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, neurological diseases, and others. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam continues to invest responsibly to broaden its geographical footprint within the region, now employing over 400 people across multiple countries including Portugal.

www.alnylam.com